Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 20 of 1,261
  1. US 12391753

    Antigen binding molecule formats

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  2. US 12391923

    SIRPα-silenced natural killer (NK) cells

    The Regents of the University of California · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  3. US 12391765

    Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies

    Takeda Pharmaceutical Company Limited · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  4. US 12391732

    Articles comprising a silk polypeptide for antigen delivery

    Ludwig-Maximilians-Universitat Munchen · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  5. US 12391920

    Models of tauopathy

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  6. WO 2025168072

    COMPOSÉS HÉTÉROCYCLIQUES, COMPOSITIONS ASSOCIÉES ET MÉTHODES DE TRAITEMENT ASSOCIÉS

    BEIGENE SUZHOU CO LTD [CN] · Granted Aug 14, 2025 · Expires Aug 9, 2045

    granted
  7. WO 2025168081

    TRAITEMENT D'UN TROUBLE PROLIFÉRATIF DES LYMPHOCYTES B AVEC UN COMPOSÉ ACTIVATEUR DE DÉGRADATION CHIMÉRIQUE

    BEIGENE SUZHOU CO LTD [CN] · Granted Aug 14, 2025 · Expires Aug 9, 2045

    granted
  8. WO 2025169901

    CONJUGUÉ ANTICORPS-MÉDICAMENT CONTENANT UN COMPOSÉ HÉTÉROCYCLIQUE PRÉSENTANT UNE ACTIVITÉ D'INDUCTION DE LA DÉCOMPOSITION DE PROTÉINES MUTANTES KRAS

    ASTELLAS PHARMA INC [JP] · Granted Aug 14, 2025 · Expires Aug 9, 2045

    granted
  9. US 12385013

    Differentiation of pancreatic endocrine cells

    Vertex Pharmaceuticals Incorporated · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  10. US 12383516

    Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solvent

    Amphastar Pharmaceuticals, Inc. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  11. US 12385026

    Stabilized alpha-galactosidase and uses thereof

    Protalix Ltd. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  12. US 12385914

    CRY1-clock-BMAL1 complex-disrupting agents and methods of identifying and using same

    The Regents of the University of California · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  13. US 12385043

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  14. US 12385012

    Methods and compositions for inducing hematopoietic cell differentiation

    Fate Therapeutics, Inc. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  15. US 12384854

    Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

    Takeda Pharmaceutical Company Limited · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  16. US 12384817

    Peptide having protective activity against cell damage caused by particulate matter, and uses for same

    CAREGEN CO., LTD. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  17. US 12384829

    Pocket engineering of HLA alleles for treating autoimmunity

    The Regents of the University of Colorado, a Body Corporate · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  18. US 12384853

    Anti-HER2/PD1 bispecific antibody

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  19. US 12384845

    Activatable masked anti-CTLA4 binding proteins

    Xilio Development, Inc. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  20. US 12383560

    Compounds and uses thereof

    FOGHORN THERAPEUTICS INC. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  21. US 12383540

    Compounds that modulates AMPA receptor function

    University College Cardiff Consultants Limited · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  22. US 12383535

    Hydrogen peroxide-responsive KEAP1-NRF2 ppi inhibitor prodrug, and preparation method therefor

    CHINA PHARMACEUTICAL UNIVERSITY · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  23. US 12383522

    Baclofen formulations and methods of minimizing patient exposure to metabolite variations

    AMNEAL PHARMACEUTICALS LLC · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  24. US 12383567

    Use of cannabinoids in the treatment of epilepsy

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.